Sort
15,273 grants matching “antimicrobial resistance”
Antimicrobial discovery from metabolomics of nematode pathogen interactions
$533,831Dennis H Kim · Massachusetts Institute Of Technology · R01 · FY2018 · AT
Defined microbial communities to prevent and eradicate infection by AMR pathogens
$533,331Robert A Britton · Baylor College Of Medicine · U19 · FY2021 · AI
Cranberry Juice and Urinary Tract Infections
$533,231Cibele T Barbosa-Cesnik · University Of Michigan At Ann Arbor · R01 · FY2006 · AT
Bacterial RNAP sigma factor structure and function
$533,193Seth A Darst · Rockefeller University · R01 · FY2014 · GM
Bacterial RNAP sigma factor structure and function
$533,193Seth A Darst · Rockefeller University · R01 · FY2015 · GM
Impact of suppressive antimicrobial therapy on the vaginal microbiota and BV
$533,080Raymond Scott McClelland · University Of Washington · R01 · FY2013 · AI
Targeting the functions of the gonococcal Type lV pilus
$532,982H. Steven Seifert · Northwestern University At Chicago · R01 · FY2022 · AI
Trehalose Pathway for Antifungal Targets and Inhibitors
$532,874Richard Gerald Brennan · Duke University · P01 · FY2017 · AI
Mechanisms of the M protein in group A Streptococcus virulence
$532,847Partho Ghosh · University Of California, San Diego · R01 · FY2011 · AI
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** THE AVIAN PATHOGENIC E. COLI (APEC) IS ONE OF THE MAJOR BACTERIAL PATHOGENS OF SIGNIFICANT CONCERNS TO THE US AND GLOBAL POULTRY INDUSTRY. APEC CAUSES WIDE RANGE OF LOCALIZED AND SYSTEMIC INFECTIONS IN POULTRY INCLUDING YOLK SAC INFECTION OMPHALITIS RESPIRATORY TRACT INFECTION SWOLLEN HEAD SYNDROME SEPTICEMIA POLYSEROSITIS COLIGRANULOMA ENTERITIS CELLULITIS AND SALPHINGITIS; COLLECTIVELY REFERRED AS COLIBACILLOSIS. COLIBACILLOSIS CULMINATES IN MULTI-MILLION DOLLARS ANNUAL LOSSES TO ALL THE FACETS OF POULTRY INDUSTRY AND REMAINS AS A SERIOUS IMPEDIMENT TO THE SUSTAINABLE POULTRY PRODUCTION WORLDWIDE. CURRENT CONTROL METHODS USING ANTIBIOTIC MEDICATION AND VACCINATION HAVE LIMITATION AS APEC IS RESISTANCE TO MULTIPLE ANTIBIOTICS AND THE AVAILABLE VACCINES FAIL TO CONFER PROTECTION AGAINST DIVERSE AND HETEROLOGOUS APEC SEROTYPES. THEREFORE DEVELOPING NEW AND POTENT ANTI-APEC THERAPEUTICS AS AN ALTERNATIVE TO CURRENT CONTROL MEASURES ARE URGENTLY NEEDED. WE PREVIOUSLY IDENTIFIED PROBIOTIC-DERIVED ANTIMICROBIAL PEPTIDES (P-1 AND P-2) THAT IN SMALL PILOT STUDIES REDUCED THE COLONIZATION OF APEC IN CECUM AND INTERNAL ORGANS OF CHICKENS. THESE PEPTIDES ARE HEAT AND PROTEOLYSIS RESISTANT EFFECTIVE AGAINST DIVERSE APEC SEROTYPES ANTIBIOTIC-RESISTANT APEC STRAINS AND AGAINST BIOFILM-PROTECTED APEC. FURTHER THESE PEPTIDES FUNCTION BY DISRUPTING OUTER MEMBRANE OF APEC A MECHANISM TO WHICH RESISTANCE IS LESS LIKELY TO OCCUR. HERE WE PLAN TO EVALUATE THE EFFICACY SAFETY AND APPLICABILITY OF IDENTIFIED ANTI-APEC PEPTIDES (P-1 AND P-2) IN DRINKING WATER OF CHICKENS AND TO ELUCIDATE THEIR MECHANISM(S) OF ACTION. OUR OVERARCHING GOAL IS TO DEVELOP THESE PEPTIDES AS NEW ANTI-APEC THERAPEUTICS AS AN ALTERNATIVE TO ANTIBIOTICS. WE EXPECT THAT THESE PEPTIDES WILL PROVIDE A NOVEL THERAPEUTIC SOLUTION TO ENHANCE THE CONTROL OF APEC INFECTIONS IN POULTRY WHICH WILL CONSEQUENTLY PROMOTE THE SUSTAINABLE POULTRY PRODUCTION AND BENEFIT THE PUBLIC HEALTH.
$532,838University Of Illinois · · FY2025 · National Institute of Food and Agriculture
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogen
$532,800Tor C. Savidge · Methodist Hospital Research Institute · P01 · FY2024 · AI
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogen
$532,800Tor C. Savidge · Methodist Hospital Research Institute · P01 · FY2025 · AI
Molecular analysis of mycobacterial NHEJ
$532,706Michael Stephen Glickman · Sloan-Kettering Inst Can Research · R01 · FY2010 · AI
Bacillus Anthracis
$532,496Mark R Deziel · Ordway Research Institute, Inc. · P01 · FY2008 · AI
Biological Treatment of Bacterial Keratitis
$532,480Chad Hall · Amebagone, Inc. · R44 · FY2018 · EY
Cumulative burden of Chlamydia trachomatis and Mycoplasma genitalium in the US: implications for screening guidelines and antimicrobial resistance
$532,352Lisa E Manhart · University Of Washington · R01 · FY2025 · AI
Structure/Function Analyses Of SP-B
$532,335Timothy Edward Weaver · Cincinnati Childrens Hosp Med Ctr · R37 · FY2006 · HL
Taste of medicines for children: genetic variation and medical adherence
$532,294Julie A Mennella · Monell Chemical Senses Center · R01 · FY2021 · DC
Revisiting alginate paradigms
$532,218Daniel J Wozniak · Ohio State University · R01 · FY2019 · AI
Novel Bacterial Pathogens in Pelvic Inflammatory Disease
$531,918Catherine L Haggerty · University Of Pittsburgh At Pittsburgh · R01 · FY2009 · AI
A synergy-based therapy against C. difficile
$531,817Kim Lewis · Northeastern University · R01 · FY2012 · AI
Mechanisms and Circumvention of Daptomycin Resistance in Streptococcus mitis
$531,783Arnold S Bayer · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · R01 · FY2019 · AI
Structural dynamics of RNAP-promoter complex in late transcription initiation
$531,694Shimon Weiss · University Of California Los Angeles · R01 · FY2020 · GM
Role of TBK1 polyubiquitination in innate antiviral immunity
$531,662Martin E Dorf · Harvard Medical School · R01 · FY2015 · AI
Role of TBK1 polyubiquitination in innate antiviral immunity
$531,662Martin E Dorf · Harvard Medical School · R01 · FY2014 · AI